Jordana Jampel

Jordana Jampel, MA

Articles by Jordana Jampel

Jordana JampelSLEEP 2025 | June 11, 2025
There are both positives and negatives associated with either testing method.
Jordana JampelSLEEP 2025 | June 11, 2025
The researchers focused on white matter microstructures in the relationship between REM-OSA and cognition decline.
Jordana JampelHIV | June 6, 2025
The nanoparticle design delivers mRNA to resting CD4+ T cells, enabling HIV reactivation without toxicity.
Jordana JampelSLEEP 2025 | June 5, 2025
Most patients switching from modafinils to solriamfetol preferred it, citing better effects; others reverted due to side effe
Jordana JampelSLEEP 2025 | June 5, 2025
The drug was well-tolerated and adverse reactions were minimal to moderate in severity.
Jordana JampelSLEEP 2025 | June 5, 2025
The researchers considered age, sex, and race/ethnicity to determine differing pathophysiologies.
Jordana JampelASCO 2025 | June 4, 2025
Forty-seven genes were linked to patient survival.
Jordana JampelASCO 2025 | June 3, 2025
Lower education level was linked to reduced access to mutational testing and clinical trials.
Jordana JampelASCO 2025 | June 3, 2025
The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment.
Jordana JampelASCO 2025 | June 2, 2025
Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens.
Jordana JampelASCO 2025 | May 30, 2025
This was an unexpected finding because mature TLS are typically rare in poorly immunogenic HPV-negative HNSCC.
Jordana JampelASCO 2025 | May 29, 2025
Tumor mutations were even detected in early-stage disease.
Jordana JampelASCO 2025 | May 29, 2025
The findings reaffirm concurrent chemoradiotherapy as a cornerstone of treatment.
Jordana JampelASCO 2025 | May 28, 2025
Patient-derived cells have the potential to enhance drug screening tools and improve patient outcomes.
Jordana JampelASCO 2025 | May 28, 2025
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Jordana JampelPulmonology | May 23, 2025
The drug significantly reduced the annual rate of moderate or severe exacerbations in eosinophilic phenotypes.
Jordana JampelDermatology | May 23, 2025
Treatment with the drug demonstrated lesion and pain control in moderate to severe disease.
Jordana JampelDermatology | May 22, 2025
Symptomatic benefits of treatment on the severity of pustules, erythema, and scaling were observed.
Jordana JampelHIV | May 20, 2025
At-home administration was safe, effective, and had higher participant satisfaction.
Jordana JampelGastroenterology | May 19, 2025
The developed scale strengthens the investigation of global irritable bowel disease epidemiology.